| Code | CSB-RA023984MB16HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to WBP-3425, targeting TNFRSF9 (Tumor Necrosis Factor Receptor Superfamily Member 9), also known as CD137 or 4-1BB. TNFRSF9 is an inducible costimulatory receptor expressed primarily on activated T cells and natural killer cells, playing a crucial role in enhancing T cell proliferation, cytokine production, and long-term survival. Upon binding to its ligand 4-1BBL, TNFRSF9 delivers potent costimulatory signals that amplify immune responses, making it a critical checkpoint in adaptive immunity. This pathway has garnered significant interest in immuno-oncology research, as TNFRSF9 agonism can enhance anti-tumor immunity, while its dysregulation has been implicated in autoimmune disorders and chronic inflammatory conditions.
WBP-3425 serves as the reference antibody for this biosimilar product, providing researchers with a reliable tool for investigating TNFRSF9 biology and immune regulation. This antibody is suitable for studies exploring T cell activation mechanisms, tumor immunology, and the development of immunotherapeutic strategies targeting the CD137 pathway.
There are currently no reviews for this product.